Acute Myeloid Leukemia Testing - Mayo Clinic Laboratories
Find out how our clinically validated testing for acute myeloid leukemia can provide critical diagnostic, prognostic, and therapeutic information for physicians.
CNS Demyelinating Disease Testing - Mayo Clinic Laboratories
We offer the only FACS assay for CNS Demyelinating Disease. Our testing ensures the highest senstivity and specificity, providing the most accurate results for patients.
Colorectal Cancer NGS Testing - Mayo Clinic Laboratories
Our panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.
Plasma-Cell Neoplasms - Mayo Clinic Laboratories
As a pioneer in the field, Mayo Clinic plays an integral role by developing new tests to help align patients with new therapies for plasma cell disorders.
Learn about our full suite of leukemia testing protocols, including includes flow cytometry, chromosome, FISH, and molecular testing.
Stiff-Person/PERM Evaluation - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay...
Results report simplifies urine test interpretation: John Lieske, M.D. - Insights
John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.
Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
NELL-1 [Test in Focus] - Insights
Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and...
RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D. - Insights
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.